1. TrinchieriG (1989) Biology of natural killer cells. Adv Immunol 47: 187–376.
2. VivierE, NunesJA, VelyF (2004) Natural killer cell signaling pathways. Science 306: 1517–1519.
3. BironCA, ByronKS, SullivanJL (1989) Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 320: 1731–1735.
4. VivierE, TomaselloE, BaratinM, WalzerT, UgoliniS (2008) Functions of natural killer cells. Nat Immunol 9: 503–510.
5. MartinMP, QiY, GaoX, YamadaE, MartinJN, et al. (2007) Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 39: 733–740.
6. FellayJ, ShiannaKV, GeD, ColomboS, LedergerberB, et al. (2007) A whole-genome association study of major determinants for host control of HIV-1. Science 317: 944–947.
7. CerboniC, NeriF, CasartelliN, ZingoniA, CosmanD, et al. (2007) Human immunodeficiency virus 1 Nef protein downmodulates the ligands of the activating receptor NKG2D and inhibits natural killer cell-mediated cytotoxicity. J Gen Virol 88: 242–250.
8. OgawaT, Tsuji-KawaharaS, YuasaT, KinoshitaS, ChikaishiT, et al. (2011) Natural killer cells recognize friend retrovirus-infected erythroid progenitor cells through NKG2D-RAE-1 interactions In Vivo. J Virol 85: 5423–5435.
9. ZelinskyyG, BalkowS, SchimmerS, WernerT, SimonMM, et al. (2007) The level of friend retrovirus replication determines the cytolytic pathway of CD8+ T-cell-mediated pathogen control. J Virol 81: 11881–11890.
10. FerlazzoG, PackM, ThomasD, PaludanC, SchmidD, et al. (2004) Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci U S A 101: 16606–16611.
11. TrinchieriG, SantoliD, GranatoD, PerussiaB (1981) Antagonistic effects of interferons on the cytotoxicity mediated by natural killer cells. Fed Proc 40: 2705–2710.
12. StaceyAR, NorrisPJ, QinL, HaygreenEA, TaylorE, et al. (2009) Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 83: 3719–3733.
13. GerlachN, SchimmerS, WeissS, KalinkeU, DittmerU (2007) Effects of Type I Interferons on Friend Retrovirus Infection (Erratum). J Virol 81: 6160.
14. GerlachN, SchimmerS, WeissS, KalinkeU, DittmerU (2006) Effects of type I interferons on Friend retrovirus infection. J Virol 80: 3438–3444.
15. AhlenstielG, EdlichB, HogdalLJ, RotmanY, NoureddinM, et al. (2011) Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology. 141: 1231–1239.
16. StegmannKA, BjorkstromNK, VeberH, CiesekS, RieseP, et al. (2010) Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 138: 1885–1897.
17. MiyazawaM, NishioJ, ChesebroB (1992) Protection against Friend retrovirus-induced leukemia by recombinant vaccinia viruses expressing the gag gene. J Virol 66: 4497–4507.
18. van PeschV, LanayaH, RenauldJC, MichielsT (2004) Characterization of the murine alpha interferon gene family. J Virol 78: 8219–8228.
19. HardyMP, OwczarekCM, JermiinLS, EjdebackM, HertzogPJ (2004) Characterization of the type I interferon locus and identification of novel genes. Genomics 84: 331–345.
20. AguetM, GrobkeM, DreidingP (1984) Various human interferon alpha subclasses cross-react with common receptors: their binding affinities correlate with their specific biological activities. Virology 132: 211–216.
21. JaksE, GavutisM, UzeG, MartalJ, PiehlerJ (2007) Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol 366: 525–539.
22. CullVS, TilbrookPA, BartlettEJ, BrekaloNL, JamesCM (2003) Type I interferon differential therapy for erythroleukemia: specificity of STAT activation. Blood 101: 2727–2735.
23. MollHP, MaierT, ZommerA, LavoieT, BrostjanC (2011) The differential activity of interferon-alpha subtypes is consistent among distinct target genes and cell types. Cytokine 53: 52–59.
24. AustinBA, JamesC, SilvermanRH, CarrDJ (2005) Critical role for the oligoadenylate synthetase/RNase L pathway in response to IFN-beta during acute ocular herpes simplex virus type 1 infection. J Immunol 175: 1100–1106.
25. HarleP, CullV, AgbagaMP, SilvermanR, WilliamsBR, et al. (2002) Differential effect of murine alpha/beta interferon transgenes on antagonization of herpes simplex virus type 1 replication. J Virol 76: 6558–6567.
26. JamesCM, AbdadMY, MansfieldJP, JacobsenHK, VindAR, et al. (2007) Differential activities of alpha/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein. Vaccine 25: 1856–1867.
27. YeowWS, LaiCM, BeilharzMW (1997) The in vivo expression patterns of individual type I interferon genes in murine cytomegalovirus infections. Antiviral Res 34: 17–26.
28. MullerU, SteinhoffU, ReisLF, HemmiS, PavlovicJ, et al. (1994) Functional role of type I and type II interferons in antiviral defense. Science 264: 1918–1921.
29. HeuselJW, WesselschmidtRL, ShrestaS, RussellJH, LeyTJ (1994) Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 76: 977–987.
30. RobertsonSJ, AmmannCG, MesserRJ, CarmodyAB, MyersL, et al. (2008) Suppression of acute anti-friend virus CD8+ T-cell responses by coinfection with lactate dehydrogenase-elevating virus. J Virol 82: 408–418.
31. BukowskiJF, WodaBA, HabuS, OkumuraK, WelshRM (1983) Natural killer cell depletion enhances virus synthesis and virus-induced hepatitis in vivo. J Immunol 131: 1531–1538.
32. GerlachN, GibbertK, AlterC, NairS, ZelinskyyG, et al. (2009) Anti-retroviral effects of type I IFN subtypes in vivo. Eur J Immunol 39: 136–146.
33. Bollati-FogolinM, MullerW (2005) Virus free, cell-based assay for the quantification of murine type I interferons. J Immunol Methods 306: 169–175.
34. DittmerU, BrooksDM, HasenkrugKJ (1998) Characterization of a live-attenuated retroviral vaccine demonstrates protection via immune mechanisms. J Virol 72: 6554–6558.
35. ChenHD, FraireAE, JorisI, WelshRM, SelinLK (2003) Specific history of heterologous virus infections determines anti-viral immunity and immunopathology in the lung. Am J Pathol 163: 1341–1355.
36. ChenW, QinH, ChesebroB, CheeverMA (1996) Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J Virol 70: 7773–7782.
37. ShimizuT, UenishiH, TeramuraY, IwashiroM, KuribayashiK, et al. (1994) Fine structure of a virus-encoded helper T-cell epitope expressed on FBL-3 tumor cells. J Virol 68: 7704–7708.
38. ZelinskyyG, KraftAR, SchimmerS, ArndtT, DittmerU (2006) Kinetics of CD8+ effector T cell responses and induced CD4+ regulatory T cell responses during Friend retrovirus infection. Eur J Immunol 36: 2658–2670.
39. ZelinskyyG, DietzeKK, HuseckenYP, SchimmerS, NairS, et al. (2009) The regulatory T-cell response during acute retroviral infection is locally defined and controls the magnitude and duration of the virus-specific cytotoxic T-cell response. Blood 114: 3199–3207.
40. CikesM, FribergSJr, KleinG (1973) Progressive loss of H-2 antigens with concomitant increase of cell-surface antigen(s) determined by Moloney leukemia virus in cultured murine lymphomas. J Natl Cancer Inst 50: 347–362.
41. McCoyJL, FeferA, GlynnJP (1967) Influence of infectious virus on the induction of transplantation resistance in the Friend tumor system. Cancer Res 27: 2267–2271.
42. KataokaT, ShinoharaN, TakayamaH, TakakuK, KondoS, et al. (1996) Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol 156: 3678–3686.
43. NeumannAU, LamNP, DahariH, GretchDR, WileyTE, et al. (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282: 103–107.
44. FeldJJ, HoofnagleJH (2005) Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436: 967–972.
45. HerrmannE, LeeJH, MarinosG, ModiM, ZeuzemS (2003) Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 37: 1351–1358.
46. GrahamGJ (2009) D6 and the atypical chemokine receptor family: novel regulators of immune and inflammatory processes. Eur J Immunol 39: 342–351.
47. ZidarDA, ViolinJD, WhalenEJ, LefkowitzRJ (2009) Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands. Proc Natl Acad Sci U S A 106: 9649–9654.
48. GrumbachIM, FishEN, UddinS, MajchrzakB, ColamoniciOR, et al. (1999) Activation of the Jak-Stat pathway in cells that exhibit selective sensitivity to the antiviral effects of IFN-beta compared with IFN-alpha. J Interferon Cytokine Res 19: 797–801.
49. DerSD, ZhouA, WilliamsBR, SilvermanRH (1998) Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 95: 15623–15628.
50. LeamanDW, Chawla-SarkarM, JacobsB, VyasK, SunY, et al. (2003) Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFN-beta compared with IFN-alpha2. J Interferon Cytokine Res 23: 745–756.
51. SeveraM, RemoliME, GiacominiE, RagimbeauJ, LandeR, et al. (2006) Differential responsiveness to IFN-alpha and IFN-beta of human mature DC through modulation of IFNAR expression. J Leukoc Biol 79: 1286–1294.
52. BironCA, NguyenKB, PienGC, CousensLP, Salazar-MatherTP (1999) Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 17: 189–220.
53. EdwardsBS, HawkinsMJ, BordenEC (1984) Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity. Cancer Res 44: 3135–3139.
54. OrtaldoJR, HerbermanRB, HarveyC, OsheroffP, PanYC, et al. (1984) A species of human alpha interferon that lacks the ability to boost human natural killer activity. Proc Natl Acad Sci U S A 81: 4926–4929.
55. VerhagenA, MackayIR, RowleyM, TymmsM (1990) Comparison of augmentation of human natural killer cell cytotoxicity by interferon-alpha subtypes. Nat Immun Cell Growth Regul 9: 325–333.
56. IwanamiN, NiwaA, YasutomiY, TabataN, MiyazawaM (2001) Role of natural killer cells in resistance against friend retrovirus-induced leukemia. J Virol 75: 3152–3163.
57. ZelinskyyG, BalkowS, SchimmerS, SchepersK, SimonMM, et al. (2004) Independent roles of perforin, granzymes, and Fas in the control of Friend retrovirus infection. Virology 330: 365–374.
58. JansDA, JansP, BriggsLJ, SuttonV, TrapaniJA (1996) Nuclear transport of granzyme B (fragmentin-2). Dependence of perforin in vivo and cytosolic factors in vitro. J Biol Chem 271: 30781–30789.
59. SimonHG, FruthU, KramerMD, SimonMM (1987) A secretable serine proteinase with highly restricted specificity from cytolytic T lymphocytes inactivates retrovirus-associated reverse transcriptase. FEBS Lett 223: 352–360.
60. SatoK, HidaS, TakayanagiH, YokochiT, KayagakiN, et al. (2001) Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur J Immunol 31: 3138–3146.
61. KayagakiN, YamaguchiN, NakayamaM, EtoH, OkumuraK, et al. (1999) Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med 189: 1451–1460.
62. KayagakiN, YamaguchiN, NakayamaM, TakedaK, AkibaH, et al. (1999) Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J Immunol 163: 1906–1913.
63. WalczakH, MillerRE, AriailK, GliniakB, GriffithTS, et al. (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157–163.
64. ZamaiL, AhmadM, BennettIM, AzzoniL, AlnemriES, et al. (1998) Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 188: 2375–2380.
65. AltfeldM, FaddaL, FrletaD, BhardwajN (2011) DCs and NK cells: critical effectors in the immune response to HIV-1. Nat Rev Immunol 11: 176–186.
66. HosmalinA, LebonP (2006) Type I interferon production in HIV-infected patients. J Leukoc Biol 80: 984–993.
67. HarmanAN, LaiJ, TurvilleS, SamarajiwaS, GrayL, et al. (2011) HIV infection of dendritic cells subverts the IFN induction pathway via IRF-1 and inhibits type 1 IFN production. Blood 118: 298–308.
68. YanN, Regalado-MagdosAD, StiggelboutB, Lee-KirschMA, LiebermanJ (2010) The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat Immunol 11: 1005–1013.
69. KamgaI, KahiS, DeveliogluL, LichtnerM, MaranonC, et al. (2005) Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection. J Infect Dis 192: 303–310.
70. FeldmanS, SteinD, AmruteS, DennyT, GarciaZ, et al. (2001) Decreased interferon-alpha production in HIV-infected patients correlates with numerical and functional deficiencies in circulating type 2 dendritic cell precursors. Clin Immunol 101: 201–210.
71. KhatissianE, ToveyMG, CumontMC, MonceauxV, LebonP, et al. (1996) The relationship between the interferon alpha response and viral burden in primary SIV infection. AIDS Res Hum Retroviruses 12: 1273–1278.